Abstract
Compared with the combination of heparin and a glycoprotein IIb/IIIa inhibitor (GPI), bivalirudin confers a lower bleeding risk but is also a less potent inhibitor of platelet aggregation. In patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment-elevation myocardial infarction (STEMI), bivalirudin alone produced significantly better clinical outcomes than heparin plus a GPI (JW …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
